Voyager Therapeutics (VYGR)
NASDAQ:VYGR
Want to see VYGR full AI Analyst Report?
Top Page
Voyager Therapeutics
(NASDAQ:VYGR)
Select Model
Select Model
Rating:47Neutral
Price Target:
$4.00
▼(-3.15% Downside)
Action:ReiteratedDate:03/18/26
The score is held down primarily by weakened financial performance (large recent losses and rising cash burn) and a loss-making valuation profile (negative P/E). Technical indicators are broadly neutral with only modest positive momentum, while corporate events are mixed, balancing leadership-transition risk with upbeat pipeline progress messaging.
Positive Factors
Capsid-engineered AAV platform
Voyager’s use of capsid-engineered AAV vectors represents a technical platform advantage for CNS gene delivery. A proprietary, well‑developed capsid platform can create durable differentiation, improve target tissue delivery, and increase partner/licensing appeal across multi-year development cycles.
Negative Factors
Accelerating cash burn
The shift to substantial operating and free cash outflows increases reliance on external funding. Persistent cash burn during clinical-stage development raises the likelihood of dilutive equity raises or partnership dependence, constraining strategic optionality and potentially slowing program timelines if financing costs rise.
Read all positive and negative factors
Positive Factors
Negative Factors
Capsid-engineered AAV platform
Voyager’s use of capsid-engineered AAV vectors represents a technical platform advantage for CNS gene delivery. A proprietary, well‑developed capsid platform can create durable differentiation, improve target tissue delivery, and increase partner/licensing appeal across multi-year development cycles.
Read all positive factors
Voyager Therapeutics (VYGR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$219.53M
Dividend YieldN/A
Average Volume (3M)840.64K
Price to Earnings (P/E)―
Beta (1Y)1.19
Revenue Growth-49.53%
EPS Growth-81.33%
CountryUS
Employees172
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.46
Shares Outstanding60,310,528
10 Day Avg. Volume663,215
30 Day Avg. Volume840,638
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.18
Price to Sales (P/S)5.71
P/FCF Ratio-1.71
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue4.66
Enterprise Value/Gross Profit4.66
Enterprise Value/Ebitda-1.51
Forecast
1Y Price Target
$14.67Price Target Upside255.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.81
Revenue Forecast (FY)$53.06M
Voyager Therapeutics Business Overview & Revenue Model
Company Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the tre...
How the Company Makes Money
Voyager Therapeutics does not primarily generate revenue from commercial product sales because it is a clinical-stage company without marketed therapies. When it does generate revenue, it is primarily from collaboration arrangements with larger bi...
Voyager Therapeutics Earnings Call Summary
Earnings Call Date:Mar 11, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The earnings call presented a positive outlook with significant advancements and strong financial positioning. Despite a setback in the SOD1 silencing program, the progress in tau-targeting therapies and potential substantial milestone payments from partnerships highlight a promising future.Positive Updates
Strong Cash Position and Potential Milestone Payments
Voyager Therapeutics reported $332 million in cash as of the end of 2024, with potential future milestone payments totaling $8.2 billion from partnerships.
Negative Updates
Setback in SOD1 Silencing Gene Therapy Program
The SOD1 silencing gene therapy program moved back into the research stage due to the payload not meeting the target profile, requiring the identification of a new payload.
Read all updates
Q4-2024 Updates
Positive
Negative
Strong Cash Position and Potential Milestone Payments
Voyager Therapeutics reported $332 million in cash as of the end of 2024, with potential future milestone payments totaling $8.2 billion from partnerships.
Read all positive updates
Company Guidance
During the Voyager Therapeutics Fourth Quarter and Year-End 2024 Financial Results Conference Call, the company provided several key metrics and updates about their progress and future plans. Voyager reported $332 million in cash as of the end of 2024 and highlighted potential future milestone payments totaling $8.2 billion, emphasizing the significance of their partnerships as a source of non-dilutive revenue. The company is advancing its tau silencing gene therapy, VY1706, into IND-enabling studies, targeting IND submission in 2026, with promising non-human primate study results showing 50% to 73% knockdown of tau messenger RNA across the brain. Additionally, the anti-tau antibody, VY7523, showed favorable results in a single ascending dose study, with a CSF to serum ratio of 0.3%. Voyager expects initial tau PET data from a multiple ascending dose study in Alzheimer's patients in the second half of 2026. They also noted their $2.9 billion in developmental milestones and guidance extending their cash runway to mid-2027.Voyager Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 40.37M | 80.00M | 250.01M | 40.91M | 37.41M |
| Gross Profit | 40.37M | 80.00M | 157.84M | -14.86M | -36.37M |
| EBITDA | -127.78M | -78.56M | 126.45M | -39.65M | -68.45M |
| Net Income | -119.72M | -65.00M | 132.33M | -46.41M | -71.20M |
Balance Sheet | |||||
| Total Assets | 252.28M | 393.05M | 351.28M | 159.36M | 193.85M |
| Cash, Cash Equivalents and Short-Term Investments | 196.45M | 266.68M | 230.88M | 118.85M | 132.54M |
| Total Debt | 36.50M | 43.73M | 20.29M | 23.13M | 44.18M |
| Total Liabilities | 56.20M | 93.29M | 114.96M | 100.34M | 98.80M |
| Stockholders Equity | 196.08M | 299.76M | 236.32M | 59.02M | 95.06M |
Cash Flow | |||||
| Free Cash Flow | -135.06M | -18.83M | 74.66M | -15.00M | -55.13M |
| Operating Cash Flow | -132.47M | -15.31M | 77.92M | -12.51M | -53.52M |
| Investing Cash Flow | 125.45M | -94.86M | -141.64M | -7.34M | 65.91M |
| Financing Cash Flow | 816.00K | 114.02M | 33.65M | 1.11M | 612.00K |
Voyager Therapeutics Technical Analysis
Positive
4.13
Price Trends
3.93
Positive
4.00
Positive
4.00
Positive
Market Momentum
>-0.01
Negative
55.44
Neutral
76.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VYGR, the sentiment is Positive. The current price of 4.13 is above the 20-day moving average (MA) of 3.94, above the 50-day MA of 3.93, and above the 200-day MA of 4.00, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.44 is Neutral, neither overbought nor oversold. The STOCH value of 76.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VYGR.
Voyager Therapeutics Risk Analysis
Voyager Therapeutics disclosed 73 risk factors in its most recent earnings report. Voyager Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Voyager Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $508.45M | -2.58 | -81.41% | ― | ― | -5.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $335.83M | -6.10 | -300.94% | ― | ― | ― | |
47 Neutral | $219.53M | -1.93 | -51.35% | ― | -49.53% | -81.33% | |
44 Neutral | $171.51M | -1.44 | 279.62% | ― | ― | ― | |
44 Neutral | $143.28M | -1.20 | -85.20% | ― | ― | 52.32% | |
43 Neutral | $148.11M | -8.62 | 25.65% | ― | ― | 35.99% |
* Healthcare Sector Average
VYGR
Voyager Therapeutics
3.64
0.08
2.25%
GALT
Galectin Therapeutics
2.25
0.88
64.23%
RNAC
Cartesian Therapeutics
6.47
-5.53
-46.08%
SLN
Silence Therapeutics
7.11
3.41
92.16%
TNYA
Tenaya Therapeutics
0.66
0.19
38.95%
KYTX
Kyverna Therapeutics, Inc.
8.40
6.09
263.64%
Voyager Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Voyager Therapeutics Announces CFO Resignation and Finance Leadership Changes
Neutral
Apr 21, 2026
On April 15, 2026, Voyager Therapeutics, Inc. announced that Chief Financial Officer Nathan Jorgensen, Ph.D. had resigned, effective May 8, 2026, to pursue a new opportunity, with the company stating his departure did not stem from any disagreemen...
Business Operations and StrategyExecutive/Board Changes
Voyager Therapeutics Announces Chief Medical Officer Resignation
Negative
Feb 12, 2026
On February 9, 2026, Voyager Therapeutics, Inc. disclosed that Chief Medical Officer Toby Ferguson, M.D., Ph.D. had tendered his resignation from the company and all subsidiary roles, effective February 20, 2026, to pursue a new opportunity. The c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.